Who
Teresa Brophy Bair
Chief Legal Officer
Company insider
Files Form 4 as: Chief Legal Officer, Kura Oncology; General Counsel, SVP Admin., Athenex.
In numbers
- Trades disclosed
- 37
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $1.6M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 5 Aug 2020
- Last trade
- 28 Sep 2026
- Last filed
- 29 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 28 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $89K8,442 at $10.50 | filing |
| 28 Sep 2026filed 29 Sep 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $89K8,442 at $10.50 | filing |
| 19 Aug 2026filed 21 Aug 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $398K31,487 at $12.63 | filing |
| 19 Aug 2026filed 21 Aug 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $398K31,487 at $12.63 | filing |
| 18 May 2026filed 20 May 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $21K2,256 at $9.38 | filing |
| 18 May 2026filed 20 May 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $21K2,256 at $9.38 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $35K4,096 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $20K2,335 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $40K4,777 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $35K4,096 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $20K2,335 at $8.46 | filing |
| 27 Jan 2026filed 27 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $40K4,777 at $8.46 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura Oncologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —100,000 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 14 Nov 2025filed 14 Nov 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $98K8,804 at $11.18 | filing |
| 13 Nov 2025filed 14 Nov 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —48,900 at $0.00 | filing |
| 29 Sep 2025filed 29 Sep 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Sold | $79K8,805 at $8.94 | filing |
| 27 Sep 2025filed 29 Sep 2025 | KURA Kura OncologyBiotechnology | SEC FORM 4 Code A | —48,900 at $0.00 | filing |
News
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in DiabetesKURA · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Teresa Brophy Bair; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.